Modern medicine stands on the bedrock of science, yet at the bedside in India, that same science often meets the messy realities of belief, misinformation and inequality. In an era where immunotherapy, genomic profiling and early detection have turned once‑hopeless diagnoses into treatable or even curable conditions, the gap between scientific progress and public trust remains stubbornly wide. Dr. Partha S. Choudhury, Director of Nuclear Medicine at Rajiv Gandhi Cancer Institute and Research Centre (RGCIRC), New Delhi, argues that bridging this gap is not merely a medical challenge, but a collective social responsibility, one that demands clearer communication from clinicians, more responsible reporting from the media and smarter, more inclusive policies from decision‑makers.
Unity in diversity is a unique slogan in India, and it resonates just as powerfully in the practice of healthcare. Although science and its development remain the foundation of medicine, healthcare at the bedside is imperfectly perfect, or vice versa. It is true that medicine has made enormous progress worldwide, and India has kept pace. Diagnostic precision has advanced dramatically. Treatments for complex diseases, including many cancers, have become more targeted, more effective, and, in some cases, genuinely curative where there was once little hope. Immunotherapy, genomic profiling, and early detection have moved from journals into clinical practice. None of this came from instinct or tradition. It came from evidence, accumulated over time.
Yet regional variations persist across India, influenced by literacy levels, family beliefs, and, often, denial in understanding the true gravity of a diagnosis. This challenge does not belong exclusively to those with limited education. Even among the educated, decisions are frequently shaped by health information consumed on social media: half-baked, attractively presented, but largely derived from non-scientific sources. A claim about a miraculous cure travels faster than a clinical explanation. A rumour about side effects, stripped of context, can deter a patient from therapy that could save a life. In cancer, cardiovascular disease, diabetes, and other serious illnesses, such delays are not neutral. They carry a cost.
We have, without question, world-class doctors in this country. But building trust in doctors is easier said than done. Trust is not built through a single campaign or a well-designed brochure. It is built through repeated, honest, and reliable engagement, with humility, local knowledge, and respect for the diversity of communities being served. What resonates in one region may be entirely unsuited to another. This is why the call to stand with science cannot be one-size-fits-all.
Financial toxicity adds another critical layer to the challenge, particularly in oncology. Out-of-pocket expenditure in India remains a major deterrent to the universal adoption of healthcare. Modern facilities are fairly widely available in tier 1 and even tier 2 cities, and they have contributed meaningfully to better treatment outcomes. But the availability of health insurance is still limited to a fraction of the population. To improve outcomes on a large scale, there must be universal access, not only to modern therapies but to the financial frameworks that make those therapies reachable for ordinary families.
The responsibility for progress is shared across society. Healthcare institutions must communicate more clearly and honestly about what they know and what they do not. Clinicians must make time, even when scarce, to explain, listen, and address patients’ fears. But the responsibility does not end with medicine. Journalists and editors shape how health stories reach the public. Policymakers determine how much investment flows into screening programmes and community-level prevention. Teachers build the health literacy that young people carry into adulthood. Trained health educators, trusted, local, and accessible, can bridge the gap between clinical knowledge and community understanding in ways that no national campaign can replicate alone.
At the heart of this is early detection. A patient who arrives early, who sought care when a symptom first appeared and was not deterred by misinformation, has far greater options than one who arrives late. The tools available at the first stage of many cancers are simply not the same as those available at the third or fourth. Early detection is not a cliche. It is often a determinant of survival, which is why public education and community outreach are part of the same continuum as clinical care.
In conclusion, the call to stand together for health is multifactorial. Modern facilities matter, but what matters equally, if not more, is literacy, awareness, knowledge about prevention, and reliable information from responsible journalism and social media. We are still some distance from achieving the goal of Health for All, but we are progressing steadily. Science is imperfect and incomplete. It remains, despite that, the most reliable foundation we have for decisions that affect human lives. Standing with it is not a gesture. It is a responsibility.
